Therapeutic RNA editing recruits naturally occurring enzymes to rewrite individual RNA letters without permanently changing genomic DNA, trading lifetime correction for reversibility and potentially simpler risk management.
BNB Plus completed a record $1.2 million LineaDNA order for LineaRx. Read what it means for scale, margins, strategy, and BNBX stock sentiment.
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone